An Open-label, Single Dose, Parallel-group Study to Evaluate the Pharmacokinetics of LCQ908 in Patients With Mild, Moderate and Severe Hepatic Impairment Compared to Age, Gender and Weight-matched Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 30 Jan 2015
At a glance
- Drugs Pradigastat (Primary)
- Indications Coronary artery disease; Hyperlipidaemia; Obesity; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Novartis
- 01 Apr 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 15 Nov 2012 Planned End Date changed from 1 Dec 2012 to 1 Jan 2013 as reported by ClinicalTrials.gov.
- 15 May 2012 New trial record